Telix Pharmaceuticals Limited (OTCMKTS:TLPPF – Get Free Report)’s stock price shot up 6.3% during mid-day trading on Wednesday . The stock traded as high as $11.8750 and last traded at $11.8750. Approximately 4,164 shares traded hands during mid-day trading, a decline of 8% from the average session volume of 4,529 shares. The stock had previously closed at $11.17.
Telix Pharmaceuticals Stock Performance
The business has a 50 day moving average of $10.02 and a 200 day moving average of $8.67.
Telix Pharmaceuticals Company Profile
Telix Pharmaceuticals is a molecularly targeted radiopharmaceutical company specializing in the development and commercialisation of diagnostic and therapeutic products for oncology and rare diseases. The company leverages radioisotopes conjugated to disease-specific targeting agents, enabling precise imaging and treatment of cancerous lesions. Telix’s portfolio includes investigational imaging compounds, such as a gallium-68-labeled prostate cancer agent, alongside therapeutic candidates that deliver beta- or alpha-emitting isotopes directly to disease sites.
Telix’s lead diagnostic program focuses on positron emission tomography (PET) imaging for prostate cancer, designed to improve detection and staging accuracy.
Read More
- Five stocks we like better than Telix Pharmaceuticals
- AirJoule Unveils Prime System, Clearing Path to Commercialization
- Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks
- Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets
- Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case
Receive News & Ratings for Telix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
